Trial reportVascular health and risk management2007
A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice.
Trial report in Vascular health and risk management, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.The Cochrane database of systematic reviews · 2014Pooled it
- Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.Journal of general internal medicine · 2012Pooled it
- Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.Cardiovascular diabetology · 2009Pooled it
- Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.Drugs & aging · 2013Trial
- ADHD and adherence to antihypertensive medication treatment: a multinational cohort study.BMC medicine · 2026Article
- Persistence to antihypertensive drug classes in uncomplicated hypertension: a nationwide Swedish cohort study.EClinicalMedicine · 2026Article
- Cautious interpretation of the findings of no increasing risk of breast cancer in users of calcium channel blockers from the population-based cohort study in Taiwan.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- First-line diuretics versus other classes of antihypertensive drugs for hypertension.The Cochrane database of systematic reviews · 2023Review
- A Multicenter Retrospective Analysis on Clinical Effectiveness and Economic Assessment of Compound Reserpine and Hydrochlorothiazide Tablets (CRH) for Hypertension.ClinicoEconomics and outcomes research : CEOR · 2020Article
- Treatment adherence among adult hypertensive patients: a cross-sectional retrospective study in primary care in Romania.Patient preference and adherence · 2018Article
- Persistence profile to nucleos(t)ide analogue treatment for patients with chronic hepatitis B.European journal of hospital pharmacy : science and practice · 2016Article
- Patient Adherence to Olmesartan/Amlodipine Combinations: Fixed Versus Extemporaneous Combinations.Journal of managed care & specialty pharmacy · 2016Article
- Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.Vascular health and risk management · 2016Review
- Cardiovascular-related healthcare resource utilization and costs in patients with hypertension switching from metoprolol to nebivolol.American health & drug benefits · 2015Article
- Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide.Clinical drug investigation · 2014Observational
- Antihypertensive drug treatment changes in the general population: the CoLaus study.BMC pharmacology & toxicology · 2014Article
- Using primary care prescribing databases for pharmacovigilance.British journal of clinical pharmacology · 2011Article
- Role of angiotensin II type 1 receptor antagonists in the treatment of hypertension in patients aged >or=65 years.Drugs & aging · 2009Review
- Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine.Vascular health and risk management · 2008Review
- Lercanidipine in the Management of Hypertension: An Update.Journal of pharmacology & pharmacotherapeuticsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistence on treatment affects the efficacy of antihypertensive treatment. We prospectively investigated the persistence on therapy and the extent of blood pressure (BP) control in 347 hypertensive patients (age 59.4 +/- 6 years) randomly allocated to a first-line treatment with: angiotensin-converting enzyme (ACE) inhibitors, calcium-channel blockers (CCBs), beta-blockers, angiotensin-II receptor blockers (ARBs), or diuretics and followed-up for 24-months. Persistence on treatment was higher in patients treated with ARBs (68.5%) and ACE inhibitors (64.5%) vs CCBs (51.6%; p < 0.05), beta-blockers (44.8%, p < 0.05), and diuretics (34.4%, p < 0.01). No ARB, ACE inhibitor, beta-blocker, or diuretic was associated with a higher persistence in therapy compared with the other molecules used in each therapeutic class. The rate of persistence was significantly higher in patients treated with lercanidipine vs others CCBs (59.3% vs 46.6%, p < 0.05). Systolic and diastolic BP was decreased more successfully in patients treated with ARBs (-11.2/-5.8 mmHg), ACE inhibitors (-10.5/-5.1 mmHg), and CCBs (-8.5/-4.6 mmHg) compared with beta-blockers (-4.0/-2.3 mmHg p < 0.05) and diuretics (-2.3/-2.1 mmHg, p < 0.05). No ARB, ACE inhibitor, beta-blocker, or diuretic was associated with a higher BP control compared with the other molecules used in each therapeutic class. A trend toward a better BP control was observed in response to lercanidipine vs other CCBs (p = 0.059). The present results confirm the importance of persistence on treatment for the management of hypertension in clinical practice.
Indexed as
Identifiers
18200818PMC2350135W2341471426What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.